港交所又有18A新股大涨。10月15日，轩竹生物（02575.HK）登陆港交所。上市首日，轩竹生物大幅收 涨126.72%。据了解，轩竹生物系四环医药（00460.HK）旗下公司，曾申报科创板IPO未果。作为一家 创新药企，轩竹生物已有三款产品获批上市。不过，轩竹生物目前尚未扭亏。成功登陆港交所，也为公 司后续发展打开了新的想象空间。值得一提的是，近几个月的几只18A新股，上市首日表现均不俗。诸 如，银诺医药上市首日收涨206.48%，劲方医药上市首日收涨106.47%等。 于未经过间变性淋巴瘤激酶（ALK）抑制剂治疗的ALK阳性的局部晚期或转移性非小细胞肺癌 （NSCLC）患者的治疗。 针对公司相关问题，北京商报记者向轩竹生物方面发去采访函，截至记者发稿，未收到公司回复。 报告期内持续亏损 上市首日收涨126.72% 10月15日，轩竹生物在港交所挂牌上市。公司股票高开153.97%，开盘价报29.46港元/股，盘中一度涨 逾160%，尾盘涨幅收窄，收于26.3港元/股，收涨126.72%，总市值为136.2亿港元。 根据配发结果，轩竹生物全球发售6733.35万股H股，香港公开发售占10%，国际发售占90 ...

Core Viewpoint - The successful debut of Xuan Bamboo Biotech (02575.HK) on the Hong Kong Stock Exchange, with a first-day surge of 126.72%, reflects a positive market sentiment towards biotech stocks, particularly those listed under the 18A category [1][3][7] Company Overview - Xuan Bamboo Biotech is a subsidiary of Sihuan Pharmaceutical (00460.HK) and has previously attempted to list on the STAR Market without success [1][3] - The company has three approved products and is actively developing over ten drug assets targeting various diseases, including gastrointestinal disorders, tumors, and non-alcoholic fatty liver disease [3][4] Financial Performance - Despite the successful listing, Xuan Bamboo Biotech reported continuous losses, with projected losses increasing in 2024. Revenue figures for 2023 and 2024 are 29,000 yuan and 30.09 million yuan, respectively, with losses of 301 million yuan and 556 million yuan for the same periods [5][6] - The increase in losses is attributed to reduced revenue and rising administrative expenses, particularly due to stock-based compensation for management and staff [6] Market Sentiment and Trends - The recent performance of 18A new stocks, including Xuan Bamboo Biotech, indicates a recovery in investor confidence in the biotech sector, with several stocks experiencing significant first-day gains [1][7] - The overall market sentiment towards the biotech industry has improved, driven by increased global focus on biopharmaceutical research and technological advancements [7]